CRSP - CRISPR Therapeutics AG
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 63.04 |
| Open | 63.04 |
| Bid | 64.51 x 1000 |
| Ask | 65.30 x 800 |
| Day's Range | 61.66 - 65.69 |
| 52 Week Range | 38.94 - 86.95 |
| Volume | |
| Avg. Volume | 1,311,469 |
| Market Cap | 5.098B |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.81 |
| Earnings Date | May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.54 |
Fair Value
Related Research
Motley Fool3 Top Healthcare Stocks to Buy for June
No matter what the economy is doing, healthcare stocks make a great long-term bet. Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery. Today, Intuitive has an installed base of more than 7,700.
Motley FoolCRISPR Therapeutics: A Galaxy's Worth of Deep Value
CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia. What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics.
Simply Wall St.CRISPR Therapeutics (NASDAQ:CRSP) shareholders are still up 11% over 1 year despite pulling back 3.8% in the past week
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...
Motley Fool3 Disruptors I Love Right Now
Disruptive companies often deliver the largest investment returns as they transform industries and grow into giants. Of course, for every Alphabet, Meta Platforms, and Amazon, there are hundreds of promising businesses that flame out. Investors with high risk tolerance need to consider market opportunity and competitive advantages when choosing where to put their money.
Motley FoolPrediction: These 2 Stocks Could Double In the Next Year
The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. CRISPR Therapeutics is a gene-editing-focused biotech with no product on the market. The company has submitted regulatory applications for its leading candidate, exa-cel, in the U.S. and Europe.
Motley Fool3 No-Brainer Stocks to Buy for Under $100 Right Now
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Motley Fool2 Supercharged Stocks to Buy With $100
It's important to take a look at the company's long-term prospects and its path to get there. The other is an innovative biotech with potentially exciting news on the horizon. Carnival (NYSE: CCL) (NYSE: CUK) is bouncing back after a tough time during the early pandemic days.
Motley Fool2 Top Trends to Invest $5,000 in Right Now
Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years. Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.
Motley FoolBetter Growth Stock: CRISPR Therapeutics vs. Teladoc Health
CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.
Investor's Business DailyCRISPR Therapeutics Stock Joins Rank Of Stocks With RS Ratings Over 90
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Motley FoolCathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
On May 10, Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) made two sales of CRISPR Therapeutics (NASDAQ: CRSP) stock, dumping more than 249,500 shares. In case you're out of the loop, CRISPR Therapeutics is a clinical-stage biotech company that's using the CRISPR-Cas9 gene editing system that it's named after to create treatments for hereditary hematologic disorders, cancers, and even diabetes. Its lead program, exa-cel, is currently being reviewed by regulators at the U.S. Food and Drug Administration (FDA), and if it gets approved, it will be used to treat both sickle cell disease and beta thalassemia, a pair of hereditary blood disorders.
Motley Fool2 Stocks You'll Be Glad You Bought at These Prices
Last year, the stock market went into a downward spiral, and growth stocks as a group were dragged down more than most. This year, the stock market appears to be recovering. Before their likely rebounds make them too expensive, here are two growth stocks to consider investing in now.
Motley Fool2 Soaring Growth Stocks That Could Rocket Even Higher
The Vanguard Growth ETF has already gained 19% in 2023. For investors with either CRISPR Therapeutics (NASDAQ: CRSP) or Nanox (NASDAQ: NNOX) in their portfolios, it's already been a great year. Shares of CRISPR Therapeutics are up more than 57% since the end of 2022.
TheStreet.comWhy Are CRISPR Therapeutics Charts Saying 'Buy'?
Gene editing firm CRISPR Therapeutics has rallied since it reported earnings last Monday. Let's check out the charts. In this daily bar chart of CRSP, below, I see a bullish set up. Prices trade above the rising 50-day moving average line and above the still declining 200-day moving average line.
Motley FoolIs CRISPR Therapeutics Stock a Buy Now?
A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share. As of Tuesday afternoon, the biotech stock was at $64. While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet.
Motley FoolWhy These 3 Nasdaq Stocks Were Glowing Green This Week
Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Among the best performers within the growth stock landscape this week were biopharmaceuticals.
Investor's Business DailyCRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics cleared that benchmark Wednesday, with a jump from 69 to 89 Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
- Simply Wall St.
CRISPR Therapeutics First Quarter 2023 Earnings: Beats Expectations
CRISPR Therapeutics ( NASDAQ:CRSP ) First Quarter 2023 Results Key Financial Results Revenue: US$100.0m (up by US$99.1m...
Motley FoolWhy CRISPR Therapeutics Stock Is on Fire Today
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.
ZacksCRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
ZacksCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA- -Enrollment and dosing ongoing for CTX110®,
Motley Fool1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
Growth stocks have performed surprisingly well in 2023. Despite ever-rising interest rates, a possible recession, and a regional banking crisis, the growth-oriented Nasdaq Composite has ticked higher by an impressive 14.8% so far this year. Which growth stocks ought to continue to march northward in the second quarter of the year and beyond?
Motley Fool3 Top Healthcare Stocks to Buy in May
Healthcare stocks always make a great addition to long-term portfolios. Most of us know Pfizer (NYSE: PFE) well for one particular product -- the COVID-19 vaccine. After all, the company dominates the market and has brought in billions of dollars in revenue from the vaccine over the past two years.
- Zacks
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
